Show simple item record

DIRECT ANTIVIRALS FOR THE TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION. EXPERIENCE IN 106 PATIENTS

Nuevas terapias orales de acción directa para tratamiento de virus de hepatitis C (VHC).

dc.contributoren-US
dc.contributorFONDECYT #1130357 y FONIS #SA16I0134 (AS). FONIS #SA14ID0129 (FF)es-ES
dc.creatorVargas, Jose Ignacio; Departamento de Gastroenterología Facultad de Medicina Pontificia Universidad Católica de Chile.
dc.creatorArab, Juan Pablo; Departamento de Gastroenterología Facultad de Medicina Pontificia Universidad Católica de Chile.
dc.creatorMonrroy, Hugo; Departamento de Gastroenterología Facultad de Medicina Pontificia Universidad Católica de Chile.
dc.creatorLabbe, Pilar; Departamento de Gastroenterología Facultad de Medicina Pontificia Universidad Católica de Chile.
dc.creatorSarmiento, Valeska; Unidad de Hepatología Hospital Gustavo Fricke Viña del Mar
dc.creatorFuster, Felipe; Unidad de Hepatología Hospital Gustavo Fricke Viña del Mar
dc.creatorBarrera, Francisco; Departamento de Gastroenterología Facultad de Medicina Pontificia Universidad Católica de Chile.
dc.creatorBenítez, Carlos; Departamento de Gastroenterología Facultad de Medicina Pontificia Universidad Católica de Chile.
dc.creatorArrese, Marco; Departamento de Gastroenterología Facultad de Medicina Pontificia Universidad Católica de Chile.
dc.creatorFuster, Francisco; Unidad de Hepatología Hospital Gustavo Fricke Viña del Mar
dc.creatorSoza, Alejandro; Departamento de Gastroenterología Facultad de Medicina Pontificia Universidad Católica de Chile.
dc.date2017-11-17
dc.date.accessioned2019-11-11T18:28:23Z
dc.date.available2019-11-11T18:28:23Z
dc.identifierhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/view/5693
dc.identifier.urihttps://revistaschilenas.uchile.cl/handle/2250/111579
dc.descriptionBackground: The availability of direct-acting antivirals (DAA) for the treatment of chronic hepatitis C virus (HCV) infection is just starting to expand in Chile. Aim: To report the initial experience of patients treated with DAA and their evolution after treatment. Material and methods: Prospective cohort study, from June 2013 to August 2016 of patients treated with DAA for HCV in three clinical centers. The presence of cirrhosis, clinical and laboratory features; adverse events (AE) and post-treatment changes in liver function were evaluated. Sustained viral response at 12 weeks post-treatment (SVR12) was determined. Results: One hundred six patients aged 58 ± 13 years, 54% males, were included. HCV genotype 1b was present in 88% and 47% had cirrhosis. Treatment regimens were asunaprevir + daclatasvir (DCV) in 17% of patients, paritaprevir / ritonavir / ombitasvir + dasabuvir in 33%, sofosbuvir (SOF) + DCV in 19%, and SOF + ledipasvir in 30%. Twenty five percent of patients used generic drugs. SVR12 was 92.1%, with no differences between generic and brand-name drugs. Serious AE were recorded in 22% of patients, being more common in those with cirrhosis (34% vs 11.5%, p < 0.01). At 12 weeks post-treatment follow-up, there was a decrease in aminotransferase values (pen-US
dc.descriptionBackground: The availability of direct-acting antivirals (DAA) for the treatment of chronic hepatitis C virus (HCV) infection is just starting to expand in Chile. Aim: To report the initial experience of patients treated with DAA and their evolution after treatment. Material and methods: Prospective cohort study, from June 2013 to August 2016 of patients treated with DAA for HCV in three clinical centers. The presence of cirrhosis, clinical and laboratory features; adverse events (AE) and post-treatment changes in liver function were evaluated. Sustained viral response at 12 weeks post-treatment (SVR12) was determined. Results: One hundred six patients aged 58 ± 13 years, 54% males, were included. HCV genotype 1b was present in 88% and 47% had cirrhosis. Treatment regimens were asunaprevir + daclatasvir (DCV) in 17% of patients, paritaprevir / ritonavir / ombitasvir + dasabuvir in 33%, sofosbuvir (SOF) + DCV in 19%, and SOF + ledipasvir in 30%. Twenty five percent of patients used generic drugs. SVR12 was 92.1%, with no differences between generic and brand-name drugs. Serious AE were recorded in 22% of patients, being more common in those with cirrhosis (34% vs 11.5%, p < 0.01). At 12 weeks post-treatment follow-up, there was a decrease in aminotransferase values (pes-ES
dc.formatapplication/pdf
dc.languagespa
dc.publisherRevista Médica de Chilees-ES
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/view/5693/3460
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/5693/27752
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/5693/27753
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/5693/27755
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/5693/27754
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/5693/27756
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/5693/27757
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/5693/27759
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/5693/27760
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/5693/27761
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/5693/27762
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/5693/27763
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/5693/27764
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/5693/27878
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/5693/27879
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/5693/31876
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/5693/31877
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/5693/31878
dc.sourceRevista Médica de Chile; Vol. 145, núm. 10 (2017): OCTUBRE 2017es-ES
dc.source0034-9887
dc.subjectAntiviral Agents; Chile; Drugs, Generic; Fibrosis; Hepatitis C; Latin Americaen-US
dc.subjectAntiviral Agents; Chile; Drugs, Generic; Fibrosis; Hepatitis C; Latin Americaes-ES
dc.titleDIRECT ANTIVIRALS FOR THE TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION. EXPERIENCE IN 106 PATIENTSen-US
dc.titleNuevas terapias orales de acción directa para tratamiento de virus de hepatitis C (VHC).es-ES
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.typees-ES


This item appears in the following Collection(s)

Show simple item record